XYRA Announces First Patient Dosed in Europe in the Phase 2/3 HARBOR-AF Study of Budiodarone in Paroxysmal and Persistent Atrial Fibrillation

Financial Post Financial Post

LOS ALTOS, California, Aug. 31, 2026 (GLOBE NEWSWIRE) — Open-label, dose-escalation study using cardiac rhythm data from implantable and wearable AF monitors allows the treating physician to titrate the dose of budiodarone monthly.

First European patient dosed in CLN-209 (HARBOR-AF) Study is the first to titrate an antiarrhythmic drug against continuously monitored AF burden (AFB) […]

Read full article at Financial Post →